Core Viewpoint - Harrow, a leading provider of ophthalmic disease management solutions in North America, will report its financial results for Q4 and the full year of 2025 on March 2, 2026, and will host a conference call on March 3, 2026, to discuss these results and provide a business update [1]. Group 1: Financial Reporting - The financial results for the fourth quarter and year ended December 31, 2025, will be announced after market close on March 2, 2026 [1]. - A Letter to Stockholders for the fourth quarter will be posted on the "Investors" section of Harrow's website [1]. Group 2: Conference Call Details - A conference call and live webcast will take place at 8:00 a.m. Eastern Time on March 3, 2026, to discuss the financial results and provide a business update [1]. - Participants can access the live webcast on the "Investors" page of Harrow's website, and a replay will be available for one year [2]. - Telephone participants must register in advance to receive a unique dial-in number and PIN for accessing the call [2]. Group 3: Company Overview - Harrow, Inc. is a prominent provider of ophthalmic disease management solutions, offering a comprehensive portfolio of products for various eye conditions, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [3]. - The company is committed to delivering safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [3].

Core Insights - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on a comprehensive portfolio of products for various eye conditions [2] Upcoming Events - Harrow management will participate in two investor conferences in December 2025: - BTIG 5th Annual Ophthalmology Day (Virtual) on December 1, 2025, at 8:30 AM EST [1] - Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025, at 3:00 PM EST, which will be webcast live [1] Company Overview - Harrow offers solutions for conditions affecting both the front and back of the eye, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [2] - The company is committed to providing safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes [2]

Core Insights - Harrow has announced leadership changes at its subsidiary ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality [2][5] Leadership Appointments - Frank Mullery brings over 20 years of experience in healthcare and pharmaceuticals, having previously served as President of Sintetica US and held senior roles at STI Pharma and Mylan, where he led significant revenue growth and product launches [3] - Bridseida Cruz has over 25 years of experience in quality and operations, known for her work in FDA remediation and operational efficiencies, including launching a new FDA-registered compounding facility that improved throughput by 20% [4] Company Vision - Harrow's CEO Mark L. Baum expressed confidence in the new leadership, emphasizing the importance of fulfilling unmet needs in U.S. eyecare and positioning ImprimisRx as a leader in ophthalmic compounding [5] Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on safe, effective, and affordable medications for various eye conditions [6]